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Characterization of health care utilization in patients
receiving implantable cardioverter-deﬁbrillator
therapies: An analysis of the managed ventricular
pacing trial
John Rickard, MD, MPH,* David Whellen, MD, MPH, FHRS,† Lou Sherfesee, PhD,‡
Brett J. Peterson, BS,‡ Tara Nahey, DVM, PhD,‡ Anthony S. Tang, MD, FHRS,x
Kenneth A. Ellenbogen, MD, FHRS,# Alan Cheng, MD‡
From the *Cleveland Clinic Foundation, Cleveland Ohio, †Thomas Jefferson University, Philadelphia,
Pennsylvania, ‡Medtronic, Mounds View, Minnesota, xUniversity of British Colombia Vancouver, BC, and
#
Virginia Commonwealth University, Richmond, Virginia.
BACKGROUND Implantable cardioverter-deﬁbrillators (ICDs) are
effective in terminating lethal arrhythmias, but little is known about
the degree of health care utilization (HCU) after ICD therapies.
OBJECTIVE Using data from the managed ventricular pacing trial,
we sought to identify the incidence and types of HCU in ICD patients
after receiving ICD therapy (shocks or antitachycardia pacing [ATP]).
METHODS We analyzed HCU events (ventricular tachyarrhythmia
[VTA]–related, heart failure–related, ICD implant procedure–related,
ICD system–related, or other) and their association with ICD therapies
(shocked ventricular tachycardia episode, ATP-terminated ventricular
tachycardia episode, and inappropriately shocked episode).
RESULTS A total of 1879 HCUs occurred in 695 of 1030 subjects
(80% primary prevention) and were classiﬁed as follows: 133
(7%) VTA-related, 373 (20%) heart failure–related, 97 (5%) implant
procedure–related, 115 (6%) system-related, and 1160 (62%)
other. Of 2113 treated VTA episodes, 1680 (80%) received ATP
only and 433 (20%) received shocks. Stratifying VTA-related HCUs

Introduction
Implantable cardioverter-deﬁbrillators (ICDs) have been shown
to reduce all-cause mortality in patients with systolic heart failure (HF).1–3 Since their introduction over 30 years ago, ICD
implant procedures have increased4 and greater use of resources
have been required for routine care, especially soon after ICD
therapies have been delivered. The latter events have resulted
in unscheduled visits to hospitals, emergency departments
(EDs), and clinics, but the extent to which these services have
been used remains poorly understood. Understanding this in
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on the basis of the type of ICD therapy delivered, there were 25
HCUs per 100 shocked VTA episodes compared with 1 HCU per 100
ATP-terminated episodes. Inappropriate ICD shocks occurred in
8.7% of the subjects and were associated with 115 HCUs. The majority of HCUs (52%) began in the emergency department, and 66% of
all HCUs resulted in hospitalization.
CONCLUSION For VTA-related HCUs, shocks are associated with a
25-fold increase in HCUs compared to VTAs treated by ATP only.
Application of evidence-based strategies and automated device–
based algorithms to reduce ICD shocks (higher rate cutoffs, use of
ATP, and arrhythmia detection) may help reduce HCUs.
KEYWORDS Health care utilization; ICD; Shocks; ATP; Hospitalization; MVP
(Heart Rhythm 2017;14:1382–1387) © 2017 The Authors. Published by Elsevier Inc. on behalf of Heart Rhythm Society. This is
an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).

the present era of cost containment is critical in an effort to identify ways to improve health care efﬁciency. The purpose of this
investigation was to characterize health care utilizations (HCUs)
in patients receiving ICD therapies, speciﬁcally focusing on differences between shocks and antitachycardia pacing (ATP) as
well as venues of care (ED vs outpatient clinics).

Methods
Study design and participants
This is a post hoc analysis of data collected in the randomized, multicenter managed ventricular pacing (MVP) trial.5
Brieﬂy, patients aged 18 years and older who underwent a
primary or secondary prevention ICD implant procedure
per current clinical guidelines were enrolled from 2004 to
2006 at 84 centers globally and followed for up to 3 years
from device implant. Patients with a need for pacing, in

1547-5271/© 2017 The Authors. Published by Elsevier Inc. on behalf of Heart Rhythm Society.
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permanent atrial ﬁbrillation, or having a life expectancy of
,12 months were excluded. Ventricular tachyarrhythmias
(VTAs), device therapies, and utilization of health care services were collected. An ethics committee approved the
MVP protocol at each participating center, and all subjects
provided signed informed consent.

Device programming
ICD programming was standardized. Devices were programmed to detect VTAs .171 beats/min for those with
known slow ventricular tachycardia and .176 beats/min
otherwise, with the number of intervals to detect ventricular
ﬁbrillation set to 18/24. Arrhythmias between 171 and 200
beats/min received ATP as the ﬁrst 2 therapies, followed
by shocks if necessary. Arrhythmias between 200 and 250
beats/min received ATP as the ﬁrst therapy, followed by
shocks if necessary.

Data collection
Demographic data were obtained at the baseline visit.
Adverse events, HCUs, and arrhythmias stored on subjects’
devices were collected during follow-up. HCUs included unscheduled clinic and urgent care visits, ED visits, and hospitalizations. Adverse events were deﬁned as any undesirable
clinical occurrence in a subject that is related to the subject’s
cardiovascular, pulmonary, or renal system or events in
which the subject presented with symptoms compatible
with ﬂuid retention and/or decreased exercise tolerance. All
available device-recorded spontaneous arrhythmias with
electrogram information were adjudicated by an episode
review committee as true VTA or non-VTA (eg, sinus
tachycardia, atrial ﬁbrillation, and oversensing).

End points
The ﬁrst end point evaluated was the type of HCU. HCUs
were classiﬁed as (1) VTA-related, (2) HF-related, (3) ICD
implant procedure–related (such as pneumothorax or hematoma), (4) ICD system–related (including HCUs related to
inappropriate shocks or system modiﬁcations), or (5) other
(not related to HF or device). The second end point was the
type of ICD therapy–related HCUs experienced by subjects,
classiﬁed as related to a (1) shocked VTA episode, (2) ATPterminated VTA episode, or (3) shocked non-VTA episode
(inappropriately shocked). HCUs related to inappropriate
shocks were considered a subclassiﬁcation of ICD system–
related HCUs for this analysis. End points were adjudicated
by an independent adverse events committee and a subset
of the MVP Steering Committee.
ICD therapy–related HCUs
VTAs were classiﬁed into the following subcategories (for
the second end point of ICD therapy–related HCU types):





Shocked VTA episode
ATP-terminated VTA episode
Untreated VTA
Shocked non-VTA episode (inappropriately shocked)
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Table 1

Baseline demographic characteristics (N 5 1030)

Characteristic

Value

Age (y)
Sex: male
NYHA classiﬁcation
Class I
Class II
Class III
Class IV
LVEF (%)
Dilated cardiomyopathy
Ischemic
Nonischemic
Sinus node dysfunction
Left bundle branch block
Right bundle branch block
Intraventricular conduction delay
AV block (most recent)
First degree block
Second degree block
Third degree block
Supraventricular tachyarrhythmias
Paroxysmal supraventricular tachyarrhythmia
Atrial tachycardia
Atrial ﬁbrillation, atrial ﬂutter
Persistent
Paroxysmal
Ventricular tachyarrhythmias
Nonsustained VT
Sustained monomorphic VT
Sustained polymorphic VT
Unspeciﬁed sustained VT
Torsades de pointes
Ventricular ﬁbrillation, ventricular
ﬂutter, cardiac arrest
ACE inhibitors or ARBs
b-Blockers
Diuretics
Amiodarone/sotalol
Reason for ICD therapy: primary indication

62.2 6 11.9
819 (79.5)
262 (25.4)
567 (55)
193 (18.7)
2 (0.2)
34.8 6 11.9
859 (83.4)
644 (62.5)
215 (20.9)
40 (3.9)
127 (12.3)
84 (8.2)
32 (3.1%)
170 (16.5)
156 (15.1)
7 (0.7)
1 (0.1)
177 (17.2)
33 (3.2)
16 (1.6)
141 (13.7)
10 (1)
131 (12.7)
455 (44.2)
260 (25.2)
149 (14.5)
6 (0.6)
16 (1.6)
4 (0.4)
82 (8)
850 (82.5)
914 (88.7)
557 (54.1)
133 (12.9)
829 (80.5)

Values are presented as mean 6 SD or as n (%).
ACE 5 angiotensin-converting enzyme; ARB 5 angiotensin receptor
blocker; AV 5 atrioventricular; ICD 5 implantable cardioverterdeﬁbrillator; LVEF 5 left ventricular ejection fraction; NYHA 5 New York
Heart Association; VT 5 ventricular tachycardia.

Episodes that received both ATP and shocks were considered shocked VTA episodes. The committee reviewed all
HCUs with corresponding documentation of arrhythmia or
device therapy occurrence or for which the subject experienced an arrhythmia or device therapy 30 days prior. Adverse
events, the 30-day history of device-detected and treated episodes, ﬁnal episode adjudication from the episode review
committee (VTA or non-VTA), and the HCU narrative
were used to determine whether the HCU was related to
device therapy.
Final classiﬁcation of HCU type
The ﬁnal classiﬁcation of HCU relatedness for both end
points were established hierarchically: (1) VTA with subclasses of (a) shocked, (b) ATP terminated, and (c) untreated;
(2) HF; (3) ICD implant procedure; (4) ICD system
(including inappropriate shock); or (5) other.
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Table 2 Summary of VTA, shock, HF, procedure, and system
relatedness of HCUs (N 5 1030)
Relatedness

No. of HCUs
(No. of subjects)

VTA
Shocked VTA
Nonshocked VTA*
Shocked non-VTA (inappropriate shocks)
Shocked episode (unknown if VTA)
Heart failure–related and not VTA-related
Associated with procedure-related AE only
Associated with system-related AE only
Other
Total

133 (82)
110 (74)
23 (19)
72 (62)
1 (1)
373 (193)
97 (76)
43 (36)
1160 (511)
1879 (695)

AE 5 adverse event; ATP 5 antitachycardia pacing; HCU 5 health care
utilization; HF 5 heart failure; VTA 5 ventricular tachyarrhythmia.
*Reﬂects ATP-terminated VTA, untreated VTA, and VTA for which therapy
relatedness was unknown.

Statistics
Descriptive statistics were used to summarize baseline demographic characteristics. Percentages were used to show the
HCU types experienced by subjects. Cumulative incidence
curves accounting for the competing risk of all-cause mortality were generated to compare onset of treated and, specifically, shocked VTA with HCUs related to appropriate
VTA therapy. Rates at annual time points are reported along
with 95% conﬁdence intervals. Annual rates were used to
summarize the prevalence of different types of HCUs (eg,
HF-related and VTA-related). Subjects were censored at the
time of their last device interrogation for the calculation of
rates of arrhythmic episodes. The data analysis for this article
was performed using SAS/STAT software version 13.1 of the
SAS System for Windows. The cumulative incidence rate was
obtained with S-PLUS software version 8.2 for Windows.

Results
This analysis included 1030 subjects who had complete HCUrelated data, of which 824(80%) had primary prevention
indication. The complete baseline characteristics are

summarized in Table 1 and are similar to those of prior ICD
clinical studies. During a mean follow-up of 2.4 years, 1879
HCUs occurred in 695 subjects (68%). Among them, 358
HCUs (19%) were identiﬁed for further adjudication because
they were ﬂagged as being VTA or ICD therapy–related on
the clinical report form or because the patient had experienced
a VTA or ICD therapy within 30 days before the HCU. Of the
358 HCUs, 206 (57.5%)were related to VTA or shocks. With
respect to treated arrhythmias, there were 2113 episodes of
treated VTAs in 222 subjects (22%) and 616 episodes of
treated non-VTAs in 125 subjects (12%). Of all treated
VTA episodes, 1680 (80%) received ATP only and 433
(20%) received shocks. There were an additional 1219 treated
episodes in 51 subjects not adjudicated because of missing
electrograms.

HCU incidence rate and types
The 1879 observed HCUs were classiﬁed as follows: 133
VTA-related, 373 HF-related, 97 implant procedure–related,
115 system-related, 1 related to shock of unknown origin, and
1160 other (Table 2). The vast majority of HCUs (89%) were
unrelated to VTA or inappropriate shocks. Examples
included HCUs for myocardial infarction, transient ischemic
attack, and chronic obstructive pulmonary disease. Annual
rates for each HCU type in different follow-up intervals are
shown in Figure 1, which illustrates that the frequency of
therapy-related HCUs are highest in the 6 months after ICD
implantation and remain fairly constant thereafter.

ICD therapy–related HCUs
During follow-up, 206 VTA and/or therapy-related HCUs of
the following types occurred in 139 subjects: 110 (53%) for
shocked VTA episodes, 11 (5%) for ATP-terminated VTA
episodes (nonshocked VTA), 12 (6%) for untreated VTA
or VTA in which the therapy relatedness was unknown, 72
(35%) for inappropriately shocked episodes, and 1 for a
shocked episode with unknown VTA status. ATP-related
HCUs were due to dizziness/syncope, palpitations, chest

Figure 1 Annual rates for HCUs in each of the 6 periods after the implant procedure. Only HCUs relatedness to VTA, ICD therapy, heart failure, implant
procedure, or the ICD system are included. HCU 5 health care utilization; ICD 5 implantable cardioverter-deﬁbrillator; VTA 5 ventricular tachyarrhythmia.
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Figure 2 Cumulative incidence rate for ﬁrst VTA, VTA treated with antitachycardia pacing or shock, VTA treated with shock, VTA-related HCU, and shocked
VTA-related HCU accounting for competing risk of mortality. HCU 5 health care utilization; VTA 5 ventricular tachyarrhythmia.

discomfort, or, in 1 case, a phantom shock. The percentage of
patients experiencing ventricular arrhythmias and ventricular
arrhythmia–related HCUs is presented in Figure 2 and
Table 3. During 36 months, 8.7% of subjects had a VTArelated HCU and 10.3% had an inappropriately shocked
episode. Only 1.2% of the study population had an HCU
related to an ATP-terminated VTA episode, whereas 7.9%
were estimated to have had a shocked VTA-related HCU
and 7.1% had an inappropriate shock–related HCU. HCUs
from a shocked VTA resulted in a dramatic increase in
HCUs compared with a VTA treated with ATP. In fact, for
every 100 VTAs treated with an ICD shock, there were 25
HCUs as compared with 1 HCU event for every 100 VTAs
treated with ATP. The elevated HCU rate was also observed
for inappropriate shocks. For every 100 incidents of inappropriate shock, there were 30 HCUs.

Location of ICD therapy–related HCUs
The majority of ICD therapy–related HCUs started in the ED
(59%), and most resulted in hospitalization (65%) (Table 4).
Table 3

Seven percent of shock-related HCUs started in the hospital
compared with 21% of HCUs unrelated to VTA or ICD therapy. The hospital was the most frequent ﬁnal location of
shock-related HCUs (64%), followed by the clinic (21%)
and ED (14%). Sixty-ﬁve percent of shocked VTA-related
HCUs, 64% of inappropriate shock–related HCUs, and
57% of ATP-terminated or self-terminated VTA-related
HCUs resulted in hospitalization (Table 4). Most (106 of
182 [58%]) shock-related HCUs occurred in .1 location
(eg, presented in the ED and then hospitalized).

Discussion
This analysis has provided 3 important insights in our understanding of HCU after ICD therapies. First, 89% of HCUs in
typical ICD subjects are not related to the device with 20%
related to HF and 10.4% related to device therapy. Second,
shocks generate signiﬁcantly more HCUs compared with
VTA episodes terminated by ATP only. Lastly, the majority
of ICD shocks result in ED visits followed by hospitalization.

Cumulative incidence rates for VTA and HCU end points at 12, 24, and 36 mo after the implant procedure
Cumulative incidence rate (%) (95% conﬁdence interval)*

End point

12 mo

24 mo

36 mo

VTA
Treated VTA
Shocked VTA
VTA-related HCU
Shocked VTA-related HCU

18.0 (15.7–20.5)
14.2 (12.2–16.4)
7.2 (6.0–8.8)
5.1 (4.0–6.4)
4.6 (3.5–6.1)

27.1 (24.5–29.9)
21.0 (18.7–23.7)
10.3 (8.6–12.3)
7.5 (6.0–9.4)
6.7 (5.2–8.6)

31.1 (27.6–35.1)
24.8 (22.1–27.7)
12.0 (10.0–14.5)
8.7 (7.1–10.8)
7.9 (6.4–9.8)

HCU 5 health care utilization; ICD 5 implantable cardioverter-deﬁbrillator; VTA 5 ventricular tachyarrhythmia.
*Cumulative incidence rates represent the estimated percentage of subjects experiencing the end point at 12, 24, and 36 mo after the ICD implant procedure.
Rates were calculated using time-to-event methods accounting for mortality as a competing risk.
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Table 4 Summary of VTA and device therapy relatedness of HCUs
by HCU type (N 5 1030)
Relatedness
Shocked VTA
Clinic visit only
ED visit only
Clinic and ED visit
Hospitalization
Hospitalization only
Clinic visit and hospitalization
ED visit and hospitalization
Clinic visit, ED visit, and hospitalization
Nonshocked VTA (or therapy
relatedness unknown)
Clinic visit only
ED visit only
Clinic and ED visit
Hospitalization
Hospitalization only
Clinic visit and hospitalization
ED visit and hospitalization
Clinic visit, ED visit, and hospitalization
Shocked non-VTA (inappropriate shocks)
Clinic visit only
ED visit only
Clinic and ED visit
Hospitalization
Hospitalization only
Clinic visit and hospitalization
ED visit and hospitalization
Clinic visit, ED visit, and hospitalization
Shocked episode (unknown if VTA)
Other relatedness to VTA or shocks
Not related to shocks, ATP, or VTA
Clinic visit only
ED visit only
Clinic and ED visit
Hospitalization
Hospitalization only
Clinic visit and hospitalization
ED visit and hospitalization
Clinic visit, ED visit, and hospitalization
Total
Clinic visit only
ED visit only
Clinic and ED visit
Hospitalization
Hospitalization only
Clinic visit and hospitalization
ED visit and hospitalization
Clinic visit, ED visit, and hospitalization

No. of HCUs
(No. of subjects)
110 (74)
21 (15)
17 (14)
1 (1)
71 (56)
6 (5)
10 (10)
51 (41)
4 (4)
23 (19)
7 (6)
1 (1)
2 (1)
13 (13)
2 (2)
1 (1)
9 (9)
1 (1)
72 (62)
17 (16)
9 (9)
0 (0)
46 (42)
6 (5)
8 (8)
31 (30)
1 (1)
1 (1)
4 (4)
1669 (639)
295 (175)
252 (158)
7 (7)
355 (261)
355 (261)
126 (98)
594 (324)
40 (33)
1879 (695)
341 (197)
281 (175)
10 (8)
1247 (584)
369 (270)
145 (113)
687 (365)
46 (38)

Other includes cases in which relatedness to all 3 categories (VTA, device
therapy, and shocks) was unknown (n 5 1), HCU was related to device therapy but shock and VTA relatedness unknown (n 5 1), or HCU was related to
ATP-terminated non-VTA (n 5 1).
ATP 5 antitachycardia pacing; ED 5 emergency department;
HCU 5 health care utilization; VTA 5 ventricular tachyarrhythmia.

There are limited data on HCU after ICD therapy. Bhavnani et al6 showed a signiﬁcant difference in health care costs
associated with inappropriate shock (compared to no shocks)
within a year after device implant. Taken together, appropriate and inappropriate ICD shocks frequently result in

health care system utilization and subsequent costly testing.
In the current study, we similarly show that a signiﬁcant number of shock events ultimately lead to an HCU. A similar
ﬁnding, however, was not noted for ATP events where the
large majority did not lead to an HCU. ATP therapy has
been shown to terminate most ventricular tachycardia episodes and potentially improve quality of life compared
with ICD shocks.7
While reducing shocks and hence HCUs is an important
goal, our study shows that the majority of HCUs in patients
with ICD are not related to their device. While reducing
shocks will likely result in reduced HCUs, dramatic reductions are unlikely given multiple other comorbid conditions.
The potential to use device diagnostics to decrease HFrelated HCUs is an appealing idea. Although still a minority
of overall HCUs at 20%, HF-related HCUs remain an important target for cost reduction. Understanding ways in which to
reduce these events remains paramount.
Our study also found that patients who seek care after a
shock primarily present to the ED, which often leads to inpatient hospitalization. While individual practices vary, often
single shock episodes can be managed by a device clinic
either the same or the next day in clinic rather than necessitating ED care. Given the costly nature of ED and inpatient
hospital care, our data suggest that there may be room for
cost reduction via patient education in how single shock
episodes are managed.

Study limitations
Our study has several limitations. First, this was a post hoc
analysis of a randomized clinical study. Hence, all limitations
associated with this type of analysis need to be considered.
Second, the time period from when the MVP trial was conducted predated multiple trials where prolonged detection intervals, higher rate cutoffs, and improved detection
algorithms were used. While shocks are less likely with
modern-day programming,8-11 the correlation between
shocks and HCU is likely similar.

Conclusion
Overall, the majority of HCUs in the population with ICD are
not related to their device. For device-related HCUs, shocks
generate signiﬁcantly more HCUs compared to VTAs terminated by ATP. Lastly, HCUs using the ED commonly result
in hospitalization. Application of evidence-based strategies
to reduce ICD shocks, such as higher rate cutoffs, use of
ATP, improved patient counseling for postshock care, and
detection algorithms, may help reduce therapy-related
HCUs and shift them from higher to lower cost venues.
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